Truist Financial Corp. stock underperforms Tuesday when compared to competitors despite daily gains
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...
Sangamo Biosciences: Overcoming Setbacks with Strategic Partnerships and Fabry Program Potential
Jefferies analyst Maury Raycroft maintained a Buy rating on Sangamo Biosciences (SGMO – Research Report) today and set a price target of ...
Business Insider23h
Truist says ‘aggressive’ buying Axsome Therapeutics after AXS-05 ADA data
Truist analyst Joon Lee keeps a Buy rating and $150 price target on Axsome Therapeutics (AXSM) while noting that the firm is an “aggressive buyer” of the stock after the “positive” Phase 3 results in ...